-
AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development
•
US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court for the Western District of Washington, D.C., naming Genmab A/S (NASDAQ: GMAB), Profound Bio US Co., ProfoundBio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. The lawsuit alleges misappropriation of AbbVie’s trade secrets related…
-
Shanghai Pharmaceuticals Subsidiary Fined USD23 Million for Anti-Monopoly Violations
•
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) has disclosed that its subsidiary, Shanghai SINE United Pharmaceuticals Co., Ltd., received a written decision of administrative penalty from the Shanghai municipal market regulation bureau, along with an aggregate fine of RMB 166 million (USD 23 million). The penalty stems from actions…
-
Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct
•
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the China Securities Regulatory Commission (CSRC) last week. This action has triggered a delisting process by the Shenzhen Stock Exchange. The penalties were imposed after significant false records were discovered in Poly Pharm’s 2021 and 2022…
-
SMPA Suspends Indobufen Procurement After Patent Infringement Verdict
•
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) announced the suspension of procurement for indobufen, manufactured by Hunan Jiudian Pharmaceutical and Zhejiang Tongwu Biomedical, following a patent infringement verdict by the Hangzhou Intellectual Property Office. The decision highlights ongoing disputes over the drug’s patent status in China. BackgroundIndobufen, an isoindolylphenylbutyric acid derivative…
-
AstraZeneca Faces Class Action Lawsuits Over China Legal Issues
•
AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States related to recent legal issues in China, including the arrest of its former China market president, Leon Wang. The lawsuits allege that the UK-based pharmaceutical giant made misleading statements about its operations in China, failing…
-
Chipscreen’s Epidaza Patent Faces Invalidation Request Review
•
China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request filed by compatriot firm Chia Tai Tianqing relating to its Epidaza (chidamide) has been accepted for review by the China National Intellectual Property Administration (CNIPA). This development marks a significant legal milestone in the protection…
-
Novartis to Defend Entresto Patent After CAFC Ruling
•
Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for the Federal Circuit (CAFC), affirming the validity of the Entresto (sacubitril/valsartan) combination patent. This decision comes as the pediatric exclusivity period for the combination patent is set to expire in July 2025. The Swiss pharmaceutical…
-
SynCardia’s Next-Generation Artificial Heart Granted Patent in China
•
US-based SynCardia Systems, LLC., a global leader in total artificial heart technology, has announced that the China National Intellectual Property Administration has granted a patent for its next-generation total artificial heart, Emperor. This patent covers novel technology designed to eliminate external drive mechanisms by fully integrating the pumping mechanism within…
-
Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035
•
The China National Intellectual Property Administration (CNIPA) has granted Swiss pharmaceutical giant Roche (SWX: ROG) a Patent Term Extension (PTE) for its drug Evrysdi (risdiplam), under patent NO. ZL201580027306.9. This marks the first case of its kind in China, where the SMN2 splicing modifier will now enjoy patent protection until…
-
BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa
•
China-based BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), which is in the process of changing its name to BeOne Medicines Ltd, has announced a patent settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. concerning its oncology drug Brukinsa (zanubrutinib). The agreement stipulates that MSN’s generic version…
-
Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders
•
Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing a lawsuit against another semaglutide compounder, increasing the total number of such cases to 50. The Danish pharmaceutical giant, along with Eli Lilly (NYSE: LLY), has initiated legal campaigns targeting medical spas, weight loss clinics,…
-
China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting
•
The National Medical Products Administration (NMPA) of China has issued a draft proposal for the “Notice on Rewarding Internal Whistleblowers for Reporting on the Quality and Safety Issues of Drugs and Medical Devices.” The bureau is seeking public feedback from October 10 to November 9, 2024. This initiative encourages entities…
-
Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology
•
Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed in a London Stock Exchange filing its intention to pursue legal action against China’s genomics powerhouse BGI and its affiliates. The company alleges that BGI’s newly launched nanopore-based sequencing platform infringes upon or misappropriates Oxford…
-
AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute
•
AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie Inc. (ABBV) has initiated legal proceedings against BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), accusing the Chinese biotech firm of pilfering trade secrets vital to its Bruton’s tyrosine kinase (BTK) degrader program. According to…
-
US House Approves Biosecure Act with Implications for Chinese Biotech Firms
•
The US House of Representatives has taken a decisive step towards tightening biosecurity measures, voting 306-81 on September 9, 2024, to approve the US Biosecure Act, specifically the version known as H.R. 8333. This legislation, previously endorsed by the House Committee on Oversight and Accountability, mandates that any company receiving…
-
AstraZeneca Faces Investigation in China Over Data Privacy and Unapproved Drugs
•
AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, is reportedly under the spotlight in Shenzhen, China, with an investigation involving five current and former employees, as per a report by Bloomberg. The probe is said to center on potential breaches of data privacy regulations and the unauthorized importation of drugs…
-
China’s Supreme Court Deals Blow to Sanofi’s Aubagio, Confirms Patent Cancellation
•
BEIJING—In a recent development for the pharmaceutical industry, Sanofi’s multiple sclerosis therapy Aubagio (teriflunomide) has suffered a significant setback in China. According to the latest information, three decisions from China’s Supreme Court in May 2024 have upheld the cancellation of Sanofi’s formulation patents for Aubagio tablets, as requested by an…
-
Takeda’s Entyvio Receives Historic Patent Term Adjustment in China, a First for the Country
•
On August 16, a significant milestone was reached as the China National Intellectual Property Administration (CNIPA) awarded Japanese pharmaceutical company Takeda (NYSE: TAK)’s Entyvio (vedolizumab) a Patent Term Adjustment (PTA) for patent NO. ZL201711310404.0, marking the first case of its kind in China. This decision deviates from the typical Patent…
-
Peking Union Medical College Innovates with Angle Positioning Device Patent Sale
•
Peking Union Medical College Hospital (PUMCH) has announced its intention to transfer the patent for its “Angle Positioning Device in Hip Replacement Surgery” to Chinese medical firm AK Medical for RMB 550,000. This innovative device features components for positioning, forward tilt angle measurement, abduction angle measurement, and adjustment mechanisms, enabling…
-
Astellas Pharma Employee in China Formally Indicted on Espionage Suspicion
•
Astellas Pharma Inc., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange (TYO: 4503), is facing a challenging situation as one of its employees, detained in China since March 2023 on suspicion of espionage, has reportedly been formally indicted by Chinese authorities. The news was reported by Reuters, citing…
